From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Fucosyltransferase 6 is a fucosyltransferase that mediates the expression of the tetrasaccharide Sialyl-Lewis x (sLex, CD15s) on the surface of leukocytes. sLex participates in E-selectin-mediated leukocyte rolling and is related to the migration of leukocytes out of blood vessels .
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .
alpha-1,3-Fucosyltransferase (α1,3FucT) catalyzes the transfer of L-fucose moiety from guanosine diphosphate-beta-L-fucose (GDP-Fuc) to acceptor sugars. alpha-1,3-Fucosyltransferase (α1,3FucT) is often used in biochemical studies, and it can be used to form fucoglycoconjugates .
Fucosyltransferase 5 (EC:2.4.1.65, Fucosyltransferase 5, Fucosyltransferase V) is responsible for the terminal step in the synthesis of Lex, sialy-Lex, and Lea antigens .
Fucosyltransferase 11 (EC:2.4.1.-, FUT11) links alpha-l-fucose onto conalbumin glycopeptides and biantennary N-glycan acceptors. Fucosyltransferase 11 plays an important role in cancer .
Fucosyltransferase 9 (EC:2.4.1.152, FUT9) catalyzes the last step in the biosynthesis of Lewis antigen, the addition of a fucose to precursor polysaccharides. Fucosyltransferase 9 synthesizes the LeX oligosaccharide (CD15) .
Fucosyltransferase 7 (FUT7) is a golgi stack membrane protein. Fucosyltransferase 7catalyzes the final fucosylation step in the synthesis of Lewis antigens and generates a unique glycosylated product sialyl Lewis X (sLeX). Fucosyltransferase 7 catalyzes alpha-1,3 glycosidic linkages involved in the expression of sialyl Lewis X antigens .
alpha-1,2-Fucosyltransferase (α1,2FucT), i.e., alpha 1, 2-fucosyltransferase, is often used in biochemical studies. alpha-1,2-Fucosyltransferase is a rate-limiting enzyme, can catalyze the synthesis of Lewis y (a cell membrane-associated carbohydrate antigen) .
Protein O-Fucosyltransferase 1 (EC:2.4.1.221; POFUT1) is a Glycosyltransferase containing the cysteine-rich motifs as the acceptor sugar and GDP-fucose as the donor .
alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) (EC 2.4.1.65) (Hp3/4FT) can be found in Helicobacter pylori. alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) catalyzes fucose transfer from donor GDP-beta-l-fucose to the GlcNAc .
FUT8-IN-1 (Compound 37) is an inhibitor for α-1,6-fucosyltransferase (FUT8) with an KD of 49 nM and an IC50 of ca. 50 µM. FUT8-IN-1 generates a highly active naphthoquinone imine intermediate in the presence of FUT8, and inhibits the enzymatic activity of FUT8 .
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans .
Fucosyltransferase 5 (EC:2.4.1.65, Fucosyltransferase 5, Fucosyltransferase V) is responsible for the terminal step in the synthesis of Lex, sialy-Lex, and Lea antigens .
Fucosyltransferase 11 (EC:2.4.1.-, FUT11) links alpha-l-fucose onto conalbumin glycopeptides and biantennary N-glycan acceptors. Fucosyltransferase 11 plays an important role in cancer .
Fucosyltransferase 9 (EC:2.4.1.152, FUT9) catalyzes the last step in the biosynthesis of Lewis antigen, the addition of a fucose to precursor polysaccharides. Fucosyltransferase 9 synthesizes the LeX oligosaccharide (CD15) .
Fucosyltransferase 7 (FUT7) is a golgi stack membrane protein. Fucosyltransferase 7catalyzes the final fucosylation step in the synthesis of Lewis antigens and generates a unique glycosylated product sialyl Lewis X (sLeX). Fucosyltransferase 7 catalyzes alpha-1,3 glycosidic linkages involved in the expression of sialyl Lewis X antigens .
Protein O-Fucosyltransferase 1 (EC:2.4.1.221; POFUT1) is a Glycosyltransferase containing the cysteine-rich motifs as the acceptor sugar and GDP-fucose as the donor .
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica .
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
The FUT8 protein acts as a catalyst during glycosylation, specifically adding fucose in an α1-6 linkage to the first GlcNAc residue located near the N-glycan peptide chain. This enzymatic activity plays a crucial role in glycoprotein modification, contributing to the structural diversity and functional properties of N-glycans. FUT8 Protein, Human (sf9, His) is the recombinant human-derived FUT8 protein, expressed by Sf9 insect cells , with C-His labeled tag.
The FUT10 protein plays a key role in glycosylation, primarily fucosylating the innermost GlcNAc residues in biantennary N-glycans. This activity generates a core α(1->3)-fucose epitope that serves as a recognition signal for targeted degradation of misfolded glycoproteins. FUT10 Protein, Human (HEK293, His) is the recombinant human-derived FUT10 protein, expressed by HEK293 , with N-His labeled tag.
FUT8 protein catalyzes the addition of fucose to the initial GlcNAc residue in N-glycans. FUT8 Protein, Hamster (sf9, His) is the recombinant FUT8 protein, expressed by Sf9 insect cells , with C-His labeled tag.
CD15 Antibody (YA1327) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1327), targeting CD15. CD15 Antibody (YA1327) can be used for IHC-P experiment in human background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
